PCVX Vaxcyte, Inc.
Vaxcyte, Inc. (PCVX) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $1.84 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.3% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Vaxcyte, Inc.
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Sector
Healthcare
Industry
Biotechnology